CRNX, Crinetics and Jefferies

Jefferies Upgrades Crinetics Pharmaceuticals (CRNX)
Fintel reports that on January 22, 2025, Jefferies upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from Hold to Buy. Analyst Price Forecast Suggests 94.74% Upside As of December 23,
Crinetics upgraded to Buy from Hold at Jefferies
Jefferies analyst Dennis Ding upgraded Crinetics (CRNX) to Buy from Hold with an unchanged price target of $55. The firm cites the pullback in
Crinetics Pharmaceuticals (NASDAQ:CRNX) Earns “Buy” Rating from HC Wainwright
Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $81.
Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?
We recently published a list of Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks. In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against other Billionaire Joseph Edelman’s long-term stock picks.
How Does Crinetics Pharmaceuticals Inc (CRNX) Stack Up Against Its Industry Peers?
Crinetics Pharmaceuticals Inc (CRNX) stock saw a decline, ending the day at $40.59 which represents a decrease of $-7.91 or -16.31% from the prior close of $48.5. The stock opened at $46.64 and touched a low of $40.
Piper Sandler Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)
In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Crinetics Pharmaceuticals (CRNX – Research Report),
Crinetics upgraded to buy by Jefferies, atumelnant potential cited
Jefferies has upgraded Crinetics Pharmaceuticals (NASDAQ:CRNX) to buy, citing a recent pullback in the stock on investor concerns about Phase 2 data for the company's drug atumelnant in the treatment of congenital adrenal hyperplasia,
Yahoo Finance5d
Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential
In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against other biotech stocks with the biggest upside potential. While 2024 was a ...
news.stocktradersdaily14d
Trading (CRNX) With Integrated Risk Controls
GET MORE AI-GENERATED SIGNALS: January 08, 2025, 09:36 am ET, BY Simon M.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...
Nasdaq23d
CRNX Crosses Below Key Moving Average Level
In trading on Monday, shares of Crinetics Pharmaceuticals Inc (Symbol: CRNX) crossed below their 200 day moving average of $50.81, changing hands as low as $50.52 per share. Crinetics ...
The Motley Fool7d
Crinetics Pharmaceuticals (NASDAQ: CRNX)
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases ...